Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential AG and FOLFIRINOX with PD-L1 Antibody for Pancreatic Cancer
NCT07208539Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2025
- Primary completion
- Apr 2026
01
Overview
Phase 2, open-label, single-arm trial in pancreatic cancer (PC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: 18-month overall survival rate. Planned start Oct 2025; status: not yet recruiting.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07208539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208539.